114 Long-term disease course in patients with atopic dermatitis receiving dupilumab therapy: Results from the TREATgermany registry

Dupilumab was approved in the EU 2017 for treatment of moderate-to-severe atopic dermatitis (AD). The good therapeutic response described clinical trials has yet to be confirmed everyday care settings. German registry TREATgermany is largest European patients with moderate severe AD more than 1,400 currently (May 2022) enrolled. Patients are prospectively monitored and course, treatment, patient-reported outcomes (PROMs) documented. Of 564 adult initiation dupilumab at or after inclusion registry, 401 least one follow-up visit on were selected analysis. Overall, 200 contributing 1 year, 100 2 years, almost 50 ½ years while dupilumab. Three months initiation, a marked improvement severity observed: EASI-50 (EASI-75) about 80% (50%) further smaller improvements until plateau 12 reached. Results PROMs, e.g., Patient Global Assessment (PGA) Dermatology Life Quality Index (DLQI) consistent parameters. Therapy discontinuation rates reasons also reported. Clinical registries an important tool generate data effectiveness systemic therapies under real-world conditions. from show stable terms both objective disease PROMs.